Humanitarian Factor IX donation to Afghanistan
Kedrion Biopharma confirms its commitment to broaden access to therapies in developing Countries
Kedrion and Kamada seek FDA approval of IgG as a post-exposure treatment
BLA has been submitted on September 1, 2016. Companies planning for decision from FDA in mid-2017
SIPPET Study was WHF 2016 World Congress highlight
A Kedrion, Grifols and LFB supported symposium featured a lecture by Dr. Manuel Carcao
Kedrion Biopharma consolidates presence on Russian market
Joint venture with Nacimbio of RosTECH group for a technology transfer to Kirov plant
SIPPET study results published in the “New England Journal of Medicine”
This investigator-initiated clinical study involved 42 hemophilia treatment centers from all over the world
Kedrion Biopharma for Mother’s Day
We are committed to helping eliminate Rh disease worldwide by supporting initiatives like CURhE
Kedrion initiatives for World Hemophilia Day 2016
The goal is to improve access to treatments for people suffering from hemorrhagic conditions
CURhE, Global Alliance for mother and child healthcare
Kedrion among the founding members. The aim is Rh disease eradication
Kedrion Biopharma strengthens its position on the US market
Granted exclusive rights to commercialize a lifesaving drug in the US
A brand new location for KEDPlasma donors in the very center of Fürth
Plasma collected is turned into life-saving therapies to serve patients in Germany and worldwide